DAPK2 Antibody

What are the optimal applications for DAPK2 antibodies?

DAPK2 antibodies can be successfully employed in multiple applications, with particular efficacy in Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF/ICC). Most commercial antibodies are validated for Western blot applications, with dilution ratios typically ranging from 1:1000-1:5000 . For immunofluorescence applications, more concentrated antibody preparations are generally required (1:10-1:100) . When selecting a DAPK2 antibody, it's essential to review validation data for your specific application and tissue/cell type of interest.

How should DAPK2 antibodies be stored to maintain optimal activity?

DAPK2 antibodies should typically be stored at -20°C for long-term preservation. Many commercial preparations come in a storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Under these conditions, the antibodies remain stable for approximately one year after shipment. For antibodies supplied in small volumes (e.g., 20μl), some manufacturers include 0.1% BSA as a stabilizer . It's important to note that repeated freeze-thaw cycles can degrade antibody performance, so aliquoting may be beneficial for antibodies without glycerol stabilization.

What is the expected molecular weight of DAPK2 in Western blot applications?

The calculated molecular weight of DAPK2 is approximately 43 kDa, though observed molecular weights in Western blot applications typically range between 38-43 kDa . This variation may result from post-translational modifications, alternative splicing, or the specific tissue or cell line being analyzed. When interpreting Western blot results, researchers should anticipate this range rather than expecting a single precise band.

How can I validate the specificity of a DAPK2 antibody in my experimental system?

Validating DAPK2 antibody specificity requires a multi-faceted approach:

• Genetic knockdown verification: Use RNA interference to deplete DAPK2 and confirm decreased signal intensity in Western blot or immunostaining .

• Overexpression controls: Compare signals between non-transfected cells and cells transiently transfected with the DAPK2 gene .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to demonstrate signal blockade.

• Tissue panel validation: Test antibody reactivity across multiple tissues with known differential DAPK2 expression. For instance, DAPK2 shows strong expression in interstitial cells of the renal cortex .

• Cross-reactivity assessment: Verify that the antibody doesn't recognize other DAPK family members like DAPK1 or DRAK2, particularly when using polyclonal antibodies.

What are the challenges in detecting phosphorylated DAPK2, and how can they be addressed?

Detecting phosphorylated DAPK2 presents several challenges:

• Specific site phosphorylation: DAPK2 can be phosphorylated at multiple sites, with Ser289 being particularly important as an AMPK phosphorylation site that mimics calmodulin binding . Use site-specific phospho-antibodies that recognize only the phosphorylated form of interest.

• Low abundance: Phosphorylated forms may exist transiently or at low concentrations. Employ phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate) in lysis buffers to prevent dephosphorylation during sample preparation.

• Validation methodology: For site-specific phospho-antibodies, validation should include:

  • In vitro kinase assays with wild-type protein versus S289A mutant

  • Treatment of cells with AMPK activators to increase phosphorylation

  • λ-phosphatase treatment of lysates as a negative control

• Sample preparation: Rapid sample preparation is critical—flash-freeze tissues or rapidly lyse cells in buffers containing phosphatase inhibitors at 4°C.

How can I distinguish between DAPK2 and other DAPK family members in my experiments?

Distinguishing between DAPK family members requires careful antibody selection and experimental design:

When performing immunoprecipitation studies, validate antibody specificity by immunoprecipitating recombinant proteins of each family member. For immunostaining, compare expression patterns with known tissue-specific expression profiles (e.g., DAPK2 in renal cortical interstitial cells ).

What are the optimal cell models and conditions for studying DAPK2 function using antibody-based techniques?

When selecting cellular models for DAPK2 research, consider the following:

Recommended cell models:

• Cancer cell lines: HeLa, A431, and HepG2 cells show reliable DAPK2 expression

• Myeloid leukemia models: NB4 and HT93 APL cell lines show inducible DAPK2 expression upon ATRA treatment

• Renal models: For studying DAPK2 in kidney physiology, focus on interstitial cells of the renal cortex

Experimental conditions:

• For differentiation studies: Treat APL cell lines with ATRA (1 μM) for 4-6 days to observe dramatic DAPK2 induction (up to 210-fold)

• For oxidative stress studies: Assess DAPK2's role in mitochondrial integrity by measuring oxidative phosphorylation rates and mitochondrial membrane potential

• For autophagy induction: Use nutrient starvation or rapamycin treatment, then monitor LC3II/LC3I ratios and autophagosome formation

• For apoptosis studies: Examine TRAIL-induced apoptosis in cancer cells with DAPK2 knockdown versus control cells

When performing immunostaining, use antigen retrieval methods, typically citrate buffer (pH 6.0), with 10 minutes of boiling to optimize DAPK2 epitope exposure .

How should I design experiments to study DAPK2 phosphorylation and its functional consequences?

To effectively study DAPK2 phosphorylation:

• Kinase-substrate experiments:

  • Use recombinant DAPK2 (wild-type and kinase-dead K42A mutant) with AMPK in in vitro kinase assays

  • Employ phospho-specific antibodies against Ser289 for detection

  • Include S289A mutants as negative controls

• Functional analysis of phosphorylation:

  • Compare the ability of phosphorylated versus non-phosphorylated DAPK2 to phosphorylate known substrates like Beclin-1

  • Use ELISA-based assays to measure phosphorylation of myosin regulatory light chain (RLC)

  • Assess autophagy induction through LC3 puncta formation and LC3II/LC3I ratios

• Cellular models for AMPK-DAPK2 axis:

  • Activate AMPK using AICAR, metformin, or glucose deprivation

  • Monitor DAPK2 Ser289 phosphorylation and correlate with autophagy markers

  • Use AMPK inhibitors (Compound C) or AMPK knockdown to confirm specificity

• Mimicking phosphorylation:

  • Generate phosphomimetic (S289D or S289E) and phospho-deficient (S289A) DAPK2 mutants

  • Compare their subcellular localization, interactome, and functional effects on autophagy and apoptosis

What control experiments are necessary when using DAPK2 antibodies for protein interaction studies?

When investigating DAPK2 protein interactions:

• Essential controls for co-immunoprecipitation:

  • Input control (5-10% of lysate used for IP)

  • IgG control (non-specific antibody of same isotype)

  • Reciprocal IP (immunoprecipitate with antibody against interacting protein)

  • Specificity controls (DAPK2 knockdown or knockout lysates)

• Validation of direct interactions:

  • Use ELISA-based methods with recombinant proteins

  • For calcium-dependent interactions (e.g., with α-actinin-1), test in buffer containing CaM (100 nM) and CaCl₂ (10 μM)

  • For 14-3-3-β interactions, include ATP (10 μM) in the kinase buffer

• Controls for bimolecular fluorescence complementation (BiFC):

  • Empty vector controls for both fusion constructs

  • Subcellular localization controls (known interaction partners)

  • Mutant controls (kinase-dead DAPK2 K42A)

• Verification of functional consequences:

  • Assess whether interacting proteins affect DAPK2 kinase activity toward substrates like RLC

  • Evaluate subcellular localization changes upon interaction (e.g., DAPK2-α-actinin-1 at plasma membrane versus DAPK2-14-3-3-β in cytoplasm)

How do I interpret seemingly contradictory findings regarding DAPK2's role as a tumor suppressor versus oncogene?

The literature presents seemingly contradictory findings regarding DAPK2's role in cancer:

Tumor suppressor evidence:

• DAPK2 shows pro-apoptotic activity in multiple cell types

• RNA interference-mediated depletion of DAPK2 leads to decreased oxidative phosphorylation and destabilized mitochondrial membrane potential

• DAPK2 expression is downregulated in AML compared to normal granulocytes

Oncogenic evidence:

• DAPK2 is upregulated in thyroid carcinoma (TC) samples

• DAPK2 knockdown in TTA1 cells leads to reduced proliferation and restricted tumor growth

• DAPK2 promotes autophagy and activates NF-κB through autophagy-mediated I-κBα degradation

Interpretation framework:

• Tissue context matters: DAPK2 may function differently in different tissues (e.g., tumor suppressor in AML, oncogenic in thyroid carcinoma)

• Functional duality: Like many proteins involved in autophagy, DAPK2 may promote cell survival or death depending on cellular context and stress conditions

• Methodological considerations:

  • Overexpression studies may yield different results than knockdown approaches

  • Tagged DAPK2 may behave differently than endogenous protein

• Molecular partners: DAPK2's interactome (180 potential partners) may vary by cell type, altering its function

When designing experiments, include multiple cell types and both gain-of-function and loss-of-function approaches to fully characterize DAPK2's role in your system.

What are common technical issues with DAPK2 antibodies and how can they be resolved?

For antigen retrieval in IHC/IF applications, citrate buffer (pH 6.0) with 10 minutes of boiling has been successfully used for DAPK2 immunostaining in tissue sections .

How can I address variability in DAPK2 antibody performance across different species?

DAPK2 antibodies may exhibit variable cross-reactivity across species, creating challenges for comparative studies:

How can DAPK2 antibodies be utilized to study its role in the AMPK-autophagy signaling axis?

The identification of DAPK2 as an AMPK substrate opens new research directions that can be explored using antibody-based techniques:

• Phospho-specific antibody applications:

  • Use anti-phospho-Ser289 antibodies to monitor AMPK-mediated DAPK2 activation

  • Compare phosphorylation levels in response to metabolic stress, AMPK activators (AICAR, metformin), and inhibitors

  • Correlate DAPK2 phosphorylation with autophagy markers (LC3, p62)

• Mechanistic studies:

  • Immunoprecipitate phosphorylated DAPK2 to identify differential binding partners

  • Use proximity ligation assay (PLA) to detect DAPK2-Beclin-1 interactions in situ

  • Perform kinase assays with immunoprecipitated DAPK2 to measure activity toward Beclin-1

• Tissue and disease relevance:

  • Examine DAPK2 phosphorylation in tissues under metabolic stress (starvation, ischemia)

  • Compare phospho-DAPK2 levels in normal versus cancerous tissues

  • Assess DAPK2 phosphorylation in response to autophagy-modulating drugs

• Experimental protocol:

  • Treat cells with AMPK activators (e.g., AICAR 1mM for 2-4 hours)

  • Lyse cells in buffer containing phosphatase inhibitors

  • Detect phospho-DAPK2 by Western blot or immunostaining

  • Correlate with autophagy markers (LC3II/I ratio) and Beclin-1 phosphorylation

What methodologies should be employed to investigate DAPK2's context-dependent roles in cancer?

To address DAPK2's seemingly contradictory roles in different cancer contexts:

• Comprehensive expression analysis:

  • Use immunohistochemistry to survey DAPK2 expression across tumor types and grades

  • Compare with matched normal tissues

  • Correlate expression with clinical outcomes and molecular subtypes

• Functional studies across cancer models:

  • Establish consistent DAPK2 knockdown and overexpression models in multiple cancer cell lines

  • Assess fundamental parameters (proliferation, apoptosis, migration) across models

  • Compare effects on key signaling pathways (NF-κB, TGF-β, autophagy)

• Mechanistic investigation of dual roles:

  • Identify cancer-specific interacting partners through immunoprecipitation and mass spectrometry

  • Study subcellular localization changes across cancer types using immunofluorescence

  • Examine post-translational modifications using phospho-specific and other modification-specific antibodies

• In vivo validation:

  • Generate conditional DAPK2 knockout mouse models for specific tissues

  • Analyze cancer development, progression, and response to therapy

  • Use tumor tissue microarrays with DAPK2 immunostaining to correlate with patient outcomes

How can DAPK2 antibodies be utilized in studying its role in myeloid differentiation and leukemia?

DAPK2 has been identified as a gene repressed by PML-RARα in acute promyelocytic leukemia (APL) , suggesting important roles in myeloid differentiation:

• Differentiation studies:

  • Monitor DAPK2 expression during normal granulocytic differentiation using Western blot and immunofluorescence

  • Compare DAPK2 expression in primary AML subtypes using immunohistochemistry

  • Examine DAPK2 induction during ATRA therapy in APL patients

• Mechanism of regulation:

  • Use chromatin immunoprecipitation (ChIP) with anti-PML-RARα antibodies to verify binding at the DAPK2 promoter

  • Assess DAPK2 expression changes upon PML-RARα knockdown or ATRA treatment

  • Correlate DAPK2 expression with differentiation markers

• Functional relevance:

  • Perform DAPK2 knockdown or overexpression in APL cell lines during ATRA-induced differentiation

  • Assess impact on differentiation markers, cell morphology, and function

  • Examine effects on autophagy and apoptosis during differentiation

• Therapeutic implications:

  • Monitor DAPK2 expression as a potential biomarker of ATRA response in APL

  • Investigate DAPK2 as a therapeutic target in AML subtypes with low DAPK2 expression

  • Test combination approaches targeting DAPK2 and differentiation pathways

Experimental protocol for ATRA-induced DAPK2 expression:

• Treat NB4 or HT93 APL cells with 1μM ATRA for 4-6 days

• Collect cells at days 0, 2, 4, and 6

• Perform Western blot analysis for DAPK2 (expect 76-fold induction at day 4, 210-fold at day 6)

• Correlate with neutrophil differentiation markers